1-3 of 3
Elif Birtas
Close
Sort by
Journal Articles

Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Burhan Ferhanoglu, Zafer Gulbas, Ant Uzay, Muhit Özcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Asu Fergun Yilmaz, Derya Koyun, Nihan Alkis, Elif Birtas Atesoglu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6704–6705.
https://doi.org/10.1182/blood-2022-165385
Published: 2022
Journal Articles

Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience

A. Burhan Ferhanoglu, MD, Murat Özbalak, Ayse Salihoglu, MD, Teoman Soysal, MD, ihsan Karadoğan, Semra Paydas, MD, Evren Ozdemir, MD, Birol Yıldız, Nuri Karadurmuş, Leylagül Kaynar, Zeynep Arzu Yeğin, Ezgi Pınar Özbalak, Gülsan Sucak, Vildan Ozkocaman, MD, Pervin Topçuoğlu, Muhit Ozcan, MD, Elif Birtas, Hakan Goker, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5173.
https://doi.org/10.1182/blood.V130.Suppl_1.5173.5173
Published: 2017
Journal Articles

Rituximab-CHOP Versus CHOP Alone in Patients with Diffuse Large B Cell Lymphoma.

Mustafa Cetiner, MD, Taflan Salepci, MD, Elif Birtas Atesoglu, MD, Mahmut Gumus, MD, Aslihan Guven, MD, Levent Undar, MD, Tulin Firatli Tuglular, MD, Mahmut Bayik, MD
Journal: Blood
Blood (2006) 108 (11): 4708.
https://doi.org/10.1182/blood.V108.11.4708.4708
Published: 2006